Advertisement

Reactions Weekly

, Volume 1746, Issue 1, pp 4–4 | Cite as

Risk of pulmonary embolism with high-dose tofacitinib

News item
  • 24 Downloads

References

  1. Health Canada. Clinical trial finds an increased risk of blood clots in the lungs and of death in rheumatoid arthritis patients taking high dose of tofacitinib (sold as Xeljanz or Xeljanz XR) Internet Document : 15 Mar 2019. Available from: URL: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69336a-eng.php
  2. European Medicines Agency (EMA). Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis. Internet Document : 20 Mar 2019. Available from: URL: https://www.ema.europa.eu/en/news/increased-risk-blood-clots-lungs-death-higher-dose-xeljanz-tofacitinib-rheumatoid-arthritis

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations